Peetz Christopher reported option exercise involving 20,000 derivative units of Mirum Pharmaceuticals, Inc. at $0.00 for $0 on Nov 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CHIEF EXECUTIVE OFFICER
CHIEF EXECUTIVE OFFICER
Filed Nov 4, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
20,000Employee Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
38,487Direct
Trade date
Nov 4, 2026Option exercise
Filed
Nov 4, 2026, 8:46 PM ET1-day reporting delay
Accession
0001614740-26-000015Code M · Transaction 393119
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

MIRM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MIRM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −13%1w ago −8.3%1d ago −7%
Returns since7d +1.1%30d90d180d1y

Footnotes in full

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. F2: The stock option is fully vested.